Lazard Asset Management
CLDX icon

Lazard Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Lazard Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,075
Closed -$236K – 2165
2021
Q2 		$236K Buy
+7,075
New +$194K ﹤0.01% 1196

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Lazard Asset Management's CLDX Position: Q3 2021 in Review

Lazard Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 7,075 shares — an estimated $236K sold.

Lazard Asset Management first reported a position in CLDX in Q2 2021 and held it in 1 quarter. The position peaked at $236K in Q2 2021. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

  • Lazard Asset Management reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lazard Asset Management sold 7,075 Celldex Therapeutics shares in Q3 2021, an estimated $236K.
  • Lazard Asset Management first reported a position in Celldex Therapeutics in Q2 2021 and held it in 1 quarter.
  • Lazard Asset Management's Celldex Therapeutics position peaked at $236K in Q2 2021.
  • 160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on Lazard Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.